Melanie Shulman

5.2k total citations
18 papers, 784 citations indexed

About

Melanie Shulman is a scholar working on Psychiatry and Mental health, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Melanie Shulman has authored 18 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 6 papers in Physiology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Melanie Shulman's work include Dementia and Cognitive Impairment Research (7 papers), Alzheimer's disease research and treatments (5 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Melanie Shulman is often cited by papers focused on Dementia and Cognitive Impairment Research (7 papers), Alzheimer's disease research and treatments (5 papers) and Cholinesterase and Neurodegenerative Diseases (3 papers). Melanie Shulman collaborates with scholars based in United States, Austria and Denmark. Melanie Shulman's co-authors include ‌Barry Reisberg, Carol Torossian, Wei Zhu, Ling Leng, William Barr, Stefanie Auer, Kristin Harkins, Jason Karlawish, Robert C. Green and Wei Zhu and has published in prestigious journals such as Neurology, American Journal of Physiology-Gastrointestinal and Liver Physiology and JAMA Neurology.

In The Last Decade

Melanie Shulman

18 papers receiving 755 citations

Peers

Countries citing papers authored by Melanie Shulman

Since Specialization

Citations

This map shows the geographic impact of Melanie Shulman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Shulman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Shulman more than expected).

Fields of papers citing papers by Melanie Shulman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Shulman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Shulman. The network helps show where Melanie Shulman may publish in the future.

Co-authorship network of co-authors of Melanie Shulman

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Shulman. A scholar is included among the top collaborators of Melanie Shulman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Shulman. Melanie Shulman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease 2024 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Linda J. Van Eldik, Eric Siemers, Emily C. Collins, M. Gold, David Henley, Peter Johannsen, Hans Jörg Möbius, Melanie Shulman, (unknown), Marı́a C. Carrillo, Christopher J. Weber	1
2	TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease 2023 ·Nature Aging ·Melanie Shulman, Jessica Kong, John O’Gorman, Elena Ratti, Rajasimhan Rajagovindan, Louis Viollet, Ellen Huang, Sanjiv Sharma, Annie M. Racine, Julie Czerkowicz, Danielle Graham, Yumeng Li, Heike Hering, Samantha Budd Haeberlein	47
3	Design of a Phase 2, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia 2023 ·Alzheimer s & Dementia ·(unknown), Catherine J. Mummery, Merçé Boada, Jeffrey L. Cummings, Nick C. Fox, Oskar Hansson, Atsushi Iwata, Stephen Salloway, Anja Schneider, (unknown), Ellen Huang, Amanda Edwards, (unknown), (unknown), Lin Lin, Melanie Shulman, Jaren W. Landen, Samantha Budd Haeberlein	1
4	Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease 2023 ·JAMA Neurology ·Amanda Edwards, Jessica Collins, Candice Junge, Holly Kordasiewicz, Laurence Mignon, (unknown), Yumeng Li, Lin Lin, Jonathan M. DuBois, R. Matthew Hutchison, (unknown), Melanie Shulman, Laurent Martarello, Danielle Graham, Roger Lane, Samantha Budd Haeberlein, John D. Beaver	49
5	Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer’s disease 2020 ·Alzheimer s & Dementia ·Elena Ratti, Jessica Kong, John O’Gorman, Raj Rajagovindan, Annie M. Racine, Danielle Graham, (unknown), Louis Viollet, Stephanie Jones, (unknown), Dominic M. Walsh, Philipp von Rosenstiel, Melanie Shulman	2
6	Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial 2017 ·Dementia and Geriatric Cognitive Disorders ·‌Barry Reisberg, Yongzhao Shao, James Golomb, Isabel Monteiro, Carol Torossian, Istvan Boksay, Melanie Shulman, (unknown), Zhaoyin Zhu, (unknown), (unknown), Alok Vedvyas, Sunnie Kenowsky	9
7	The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review 2014 ·Dementia and Geriatric Cognitive Disorders ·‌Barry Reisberg, Isabel Monteiro, Carol Torossian, Stefanie Auer, Melanie Shulman, (unknown), Istvan Boksay, (unknown), Ricardo S. Osorio, (unknown), (unknown), (unknown), Sàdaf Noor, (unknown), Sunnie Kenowsky, Jinfeng Xu	34
8	Using AD biomarker research results for clinical care 2013 ·Neurology ·Melanie Shulman, Kristin Harkins, Robert C. Green, Jason Karlawish	32
9	P1‐013: Which comes first: Subjective cognitive impairment (SCI) or cognitive change? and is SCI a frequently occurring stage in the evolution of Alzheimer‐ associated cognitive change? 2010 ·Alzheimer s & Dementia ·‌Barry Reisberg, Melanie Shulman, Carol Torossian, Istvan Boksay, (unknown), Wei Zhu	2
10	Outcome over seven years of healthy adults with and without subjective cognitive impairment 2010 ·Alzheimer s & Dementia ·‌Barry Reisberg, Melanie Shulman, Carol Torossian, Ling Leng, Wei Zhu	440
11	P2‐035: Prediction of cognitive decline in normal older persons without subjective cognitive impairment: A seven year longitudinal study 2009 ·Alzheimer s & Dementia ·‌Barry Reisberg, Melanie Shulman, Carol Torossian, Stefanie Auer, Wei Zhu	37
12	The Human Brain Book 2009 ·Medical Entomology and Zoology ·Rita Carter, (unknown), (unknown), Steve Parker, Chris Frith, Uta Frith, Melanie Shulman	30
13	The clinical applications of EEG: origins 2002 ·Epilepsy & Behavior ·Melanie Shulman	4
14	Treatment of memory disorders in epilepsy 2002 ·Epilepsy & Behavior ·Melanie Shulman, William Barr	26
15	The Frontal Lobes, Epilepsy, and Behavior 2000 ·Epilepsy & Behavior ·Melanie Shulman	32
16	Serotonin, the cerebellum, and ataxia 1994 ·Journal of Epilepsy ·Melanie Shulman	5
17	Stimulation of rabbit lacrimal gland secretion with biologically active peptides 1988 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Darlene A. Dartt, Melanie Shulman, (unknown), S R Rossi, (unknown), Jeffrey P. Gilbard	20
18	A psychometric study of chronic cerebellar stimulation in man. 1976 ·PubMed ·Manuel Riklan, (unknown), Melanie Shulman, Cooper Is	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact